ArticleAntimicrobial agents and chemotherapy2015

Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment.

Guo-Jun Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.